Résumé
The emergence of glycomics has deeply stimulated the design of new bioactive glycoclusters over the past decade. Among the increasing number of multivalent synthetic structures reported so far, cyclopeptide-based glycoclusters (CBGs) have recently shown promising interest for diverse biological applications. This chapter aims at describing the major advances in this field, with a special focus on the inhibition of carbohydrate-protein interactions and the synthetic vaccines.